The $10M raise buys runway but at significant dilution (~20-25% share count increase) for a company that still needs a partnership to fund its pivotal Phase 3 DLB trial. Interim biomarker data from the Phase 2a PPA study is expected early Q4 2026 — that binary catalyst will determine whether the stock can recover from this dilutive event. Watch for partnership announcements as the primary de-risking catalyst.
Price Chart
Executive Summary
CervoMed closed a $10M registered direct offering of 2.5M shares at $4.00/share, priced at-the-market under Nasdaq rules. The dilutive capital raise provides working capital runway but significantly increases share count for a $39M market cap clinical-stage biotech that explicitly states Phase 3 initiation is contingent on partnership/additional financing.
Key Facts
- Closed registered direct offering of 2,500,000 shares of common stock at $4.00 per share
- Gross proceeds of $10 million before placement agent fees and expenses
- H.C. Wainwright & Co. acted as exclusive placement agent
- Offered under effective shelf registration statement (File No. 333-282494)
- Net proceeds to be used for working capital and general corporate purposes
- Phase 3 trial initiation for neflamapimod in DLB subject to partnership and/or additional financing
- Market cap of approximately $39M prior to offering
Financial Impact
Dilution of approximately 25% based on pre-offering share count implied by $39M market cap and $4.00 price (approx. 9.75M shares pre-offering, 2.5M new shares = ~20-25% dilution). Gross proceeds $10M.
Risk Factors
- Dilution of ~20-25% from 2.5M new shares at $4.00
- Phase 3 DLB trial initiation contingent on partnership/financing — no guarantee of terms or timing
- Clinical-stage biotech with no approved products; binary pipeline risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-021309 |
| Exhibit: ex_979559.htm | 0001437749-26-021309 |
| Document: 0001437749-26-021309-index-headers.html | 0001437749-26-021309 |
| Document: 0001437749-26-021309-index.html | 0001437749-26-021309 |
| Document: 0001437749-26-021309.txt | 0001437749-26-021309 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $2.25 $2.24 | ▼ −0.44% | ▲ +0.66% | $2.24 (−0.44%) |
Oct 13, 2026 13d ago | 8-K | $2.27 $2.29 | ▲ +0.88% | ▲ +1.96% | $2.24 (−1.32%) |
Oct 9, 2026 17d ago | 8-K | $2.51 $2.27 | ▼ −9.56% | ▼ −9.55% | $2.24 (−10.76%) |
Sep 10, 2026 6w ago | Press Release | $2.48 $2.57 | ▲ +3.63% | ▲ +2.78% | $2.24 (−9.68%) |
Aug 10, 2026 11w ago | 8-K | $3.09 $3.07 | ▼ −0.65% | ▼ −0.90% | $2.24 (−27.51%) |
Aug 4, 2026 11w ago | 8-K | $2.80 $2.81 | ▲ +0.36% | ▲ +0.56% | $2.24 (−20.00%) |
Aug 4, 2026 11w ago | Press Release | $2.80 $2.81 | ▲ +0.36% | ▲ +0.56% | $2.24 (−20.00%) |
Jul 13, 2026 15w ago | EFFECT | $3.31 $3.08 | ▲ +6.95% | ▲ +7.30% | $2.24 (+32.33%) |
Jul 6, 2026 16w ago | S-3 | $3.42 $3.41 | ▲ +0.29% | ▼ −0.02% | $2.24 (+34.50%) |
Jun 22, 2026 18w ago | 8-K | $3.72 $3.26 | ▲ +12.37% | ▲ +12.32% | $2.24 (+39.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers